Background-Exome sequencing is a promising tool for gene mapping in Mendelian disorders. We used this technique in an attempt to identify novel genes underlying monogenic dyslipidemias. Methods and Results-We performed exome sequencing on 213 selected family members from 41 kindreds with suspected Mendelian inheritance of extreme levels of low-density lipoprotein cholesterol (after candidate gene sequencing excluded known genetic causes for high low-density lipoprotein cholesterol families) or high-density lipoprotein cholesterol. We used standard analytic approaches to identify candidate variants and also assigned a polygenic score to each individual to account for their burden of common genetic variants known to influence lipid levels. In 9 families, we identified likely pathogenic variants in known lipid genes (ABCA1, APOB, APOE, LDLR, LIPA, and PCSK9); however, we were unable to identify obvious genetic etiologies in the remaining 32 families, despite follow-up analyses. We identified 3 factors that limited novel gene discovery: (1) imperfect sequencing coverage across the exome hid potentially causal variants; (2) large numbers of shared rare alleles within families obfuscated causal variant identification; and (3) individuals from 15% of families carried a significant burden of common lipid-related alleles, suggesting complex inheritance can masquerade as monogenic disease. Conclusions-We identified the genetic basis of disease in 9 of 41 families; however, none of these represented novel gene discoveries. Our results highlight the promise and limitations of exome sequencing as a discovery technique in suspected monogenic dyslipidemias. Considering the confounders identified may inform the design of future exome sequencing studies.
E xome sequencing refers to the use of next generation sequencing (NGS) technology 1 to sequence all protein-coding regions of the genome. This approach has emerged as a promising tool for gene discovery in families with suspected monogenic disorders, 2 with some reports suggesting a success rate in excess of 50%. 3 Identifying the genetic basis underlying monogenic forms of dyslipidemia has revealed insights into human biology 4 and spurred the development of novel therapeutics. 5 In an attempt to map novel dyslipidemia genes, we performed exome sequencing on 213 selected family members from 41 kindreds with suspected Mendelian inheritance of extreme levels of lowdensity lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C). To enrich for novel gene discoveries, we excluded probands from high LDL-C families that had mutations in genes known to cause monogenic hypercholesterolemia.
Methods

Subject Recruitment
Forty-one families of European ancestry with suspected Mendelian inheritance of extreme LDL-C or HDL-C levels were recruited from 8 different centers across North America and Europe. The pedigrees of these 41 families are shown in Figure I in the Data Supplement. Families A1-A9 were recruited as part of the French National Research Network on Hypercholesterolemia that includes clinicians from 11 different cities in France. Probands were selected if they met the following criteria: total and LDL-C levels above the 95th percentile when compared with a sex-and age-matched French population, 6 triglyceride level below 1.5 mmol/L, and presumed autosomal dominant transmission of hypercholesterolemia in the family. Family A10 was recruited from the Preventive Cardiology/Lipid Clinic of the McGill University Health Center. Affected individuals had LDL-C concentration exceeding the 95th percentile for age-and sex-matched subjects, a plasma triglyceride concentration <1.0 mmol/L, and no known secondary causes of hypercholesterolemia. Families A11-A14 were recruited from the Lipid Clinic at the Academic Medical Center, University of Amsterdam, the Netherlands, based on a clinical diagnosis of familial hypercholesterolemia in the proband. LDL-C levels exceeding the 95th percentile when adjusted for age and sex defined affected family members. Families A15-A20 were recruited from the Lipid Clinic of the University Hospital of Palermo. The Simon-Broome Register criteria were used to clinically diagnose heterozygous autosomal dominant hypercholesterolemia after excluding secondary hypercholesterolemia. In family A20, a pathogenic mutation in LDLR (c.2390-1G/A) was discovered previously but displayed incomplete penetrance (Figure I in the Data Supplement; A20, individuals shaded in black) and was not present in the individual with the highest level of LDL-C (the proband III:1 did not carry the LDLR mutation and had LDL-C=455 mg/dL in addition to a history of myocardial infarction at the age of 35). Two other subjects (Figure I in the Data Supplement; A20, individuals shaded in blue) also showed high LDL-C and did not have the LDLR mutation. Based on a review of the pedigrees ( Figure  I in the Data Suppleement), an autosomal dominant mode of inheritance was presumed for Families A1-A20 with the exception of A13 in which an autosomal recessive mode of inheritance was presumed.
Families B1 and B2 were recruited from the University Hospital of Palermo and Modena-Reggio Emilia. Families B3-B12 were recruited from the Washington University Lipid Research Clinic. Affected individuals in these families were identified as a result of an LDL-C level corresponding to the bottom 5th percentile when adjusted for age, ethnicity, and sex. The proband (subject III:A) in family B13 was referred to the MGH Lipid Metabolism Unit as a result of an LDL-C value of 25 mg/dL. She was noted to have 4 family members with LDL-C values <47 mg/dL. An autosomal recessive mode of inheritance was presumed for family B1, whereas an autosomal dominant mode of inheritance was presumed for B2-B13 based on the pedigrees ( Figure I in the Data Supplement).
Family C1 was recruited as part of the Genomic Resource in Arteriosclerosis and Metabolic Disease at the Cardiovascular Research Institute of the University of California, San Francisco. The clinical diagnosis of familial hypoalphalipoproteinemia was based on levels of HDL-C below the 5th percentile for 5 individuals and below the 10th percentile for 1 individual when adjusted for age, sex, and the known inverse relationship between TG and HDL-C. Family C2 was recruited from the Preventive Cardiology/Lipid Clinic of the McGill University Health Center. Families C3 and C4 were recruited from the outpatient clinic for Vascular Medicine at the Academic Medical Center, University of Amsterdam, the Netherlands. Affected individuals from families C2-C4 had HDL-C concentration below the 5th percentile for age-and sex-matched subjects, a plasma triglyceride concentration <1 mmol/L, and no known secondary causes of hypoalphalipoproteinemia. An autosomal dominant mode of inheritance was presumed for families C1-C4 based on the pedigrees ( Figure I in the Data Supplement).
The probands in families D1 and D2 were ascertained from a general patient population in the center of The Netherlands and were selected based on having HDL-C levels above the 99th percentile after adjusting for age and sex. 7 Family members with HDL-C levels above the 95th percentile for age-and sex-matched subjects were considered affected. Families D3 and D4 were recruited at the Perelman School of Medicine at the University of Pennsylvania as part of a study enrolling individuals with HDL-C levels above the 75th percentile for age-, race-, and sex-matched subjects. Spouses and blood relatives of affected individuals were also recruited. An autosomal dominant mode of inheritance was presumed for families D1-D4 based on the pedigrees ( Figure I in the Data Supplement).
Causal mutations in LDLR, APOB, and PCSK9 were excluded in the probands of families A1-A20 as previously described. 8, 9 In addition, causal mutations in LDLRAP1 were excluded in the proband from family A13 in which an autosomal recessive mode of inheritance was presumed. Candidate gene sequencing was not performed in the other families.
Replication in Japanese Families
The families shown in Figure VI 
Exome Sequencing
Subsets of samples from each family were selected for exome sequencing based on DNA availability, presence of informed consent allowing for genetic studies, and prioritization of phenotypic extremes. These selected samples underwent exome sequencing at the Broad Institute. The institutional review board at the Broad Institute and all participating sites approved the study protocols and all individuals who were selected for sequencing provided informed consent. Randomly sheared genomic DNA was used as input for library construction and in-solution hybrid selection to enrich for exomic DNA as previously described. 10 In all samples except 7, 33 Mb of genomic sequence was defined as the exome and targeted using the Whole Exome Agilent 1.1 plus boosters preparation kit (Agilent Technologies, Santa Clara, CA). The remaining 7 samples underwent hybrid selection using a prior version of the Agilent whole exome preparation kit that targeted 28.6 Mb of genomic sequence. Exome-enriched DNA for each sample was then sequenced on an Illumina GA-II sequencer using 75-base pair paired-end reads. Samples were sequenced with a goal of achieving ≥20-fold coverage in ≥80% of targeted bases. Samples with <80% of targeted bases covered by ≥20 sequencing reads were not used for the primary analysis.
The Burroughs-Wheeler Alignment algorithm 11 was used to map raw sequence reads to the human reference sequence (UCSC build HG19). The Genome Analysis Toolkit (GATK version 2) 12 and SAMtools 13 were used to locally realign reads, recalibrate individual base qualities, and flag duplicate sequencing reads for removal. The GATK UnifiedGenotyper was then used to identify single nucleotide variants and small insertions and deletions in the exome target definition specific for each sample along with ≤50 flanking intronic bases. The GATK UnifiedGenotyper was used in multisample mode, and samples were grouped into 3 batches keeping related samples together when possible. The GATK Variant Score Recalibration tool was used to update the quality score of the identified variants, and SnpEff 14 was used to predict the functional consequences of each variant. The population allele frequency of each variant was estimated using the National Heart Lung and Blood Institute's Exome Sequencing Project (ESP) Exome Variant Server (http://evs.gs.washington.edu/EVS).
Analysis of Exome Sequencing Data
To exclude genetic variation unlikely to be causal for the extreme phenotype in the affected individuals from the families, we used a heuristic analytic process commonly used in the analysis of exome sequencing studies. 15 Starting with the total number of variants shared by individuals from the family, we excluded variation that did not fit the expected pattern of inheritance based on examining the pedigree. Next, we excluded common genetic variation, defined as ≥1% frequency in the population (given the extreme excess of rare alleles in the human population, 16 the exact choice of this threshold-ie, 1% or 0.01%-has little practical effect because most rare alleles within families are well below this threshold). On the assumption that a specific causal variant could not be responsible for both high and low lipid levels, we excluded variation present in the affected individuals of the opposite extreme. Finally, we excluded silent and nongenic variation as most Mendelian syndromes are caused by coding or splice site mutations that alter the protein sequence. 17 The remaining single nucleotide variants and short insertions or deletions were considered candidates. When possible, from this list of candidates, we attempted to identify variants demonstrating cosegregation with the phenotype in the extended kindred. We considered candidate mutations as causal if (1) the mutation was identified in prior publications as causal for the same phenotype; (2) if the mutation was novel but in a gene known to cause the phenotype and functionally similar to causal mutations in that gene (ie, a novel nonsense mutation occurring in a gene in which other nonsense mutations have been shown to be causal), or (3) if the mutation was novel and occurred in a novel gene but demonstrated cosegregation with the phenotype in the extended kindred. The 95% confidence intervals surrounding the success estimates were estimated from the binomial distribution.
Polygenic Score Analysis
To determine the likelihood that polygenic inheritance could explain the extreme lipid phenotype in some families, individuals with sufficient DNA (n=130) were genotyped on the Illumina HumanExome Beadchip v1.0 according to the manufacturer's recommended protocol. This genotyping array includes the single-nucleotide polymorphisms (SNPs) reported in the Global Lipids Genetic Consortium meta-analysis of genome-wide association studies of plasma lipid levels. 18 Of the 102 SNPs reported in Global Lipids Genetic Consortium (Table) , we successfully genotyped 87 SNPs plus 4 proxies (r 2 >0.9 with the Global Lipids Genetic Consortium SNP). Using all 91 SNPs (all SNPs were used for each lipid trait because some of the SNPs are associated with >1 lipid fraction), we built baseline polygenic models for the LDL-C and HDL-C phenotypes in 9134 subjects not taking lipid-lowering medications from the Ottawa Heart Study, 27 PROCARDIS, 28 and the Malmo Diet and Cancer Study 29 to obtain estimated regression coefficients. Next, we used the estimated coefficients to obtain a predicted lipid level for each individual in our study based on these 91 SNPs. This predicted lipid level was the population mean plus the sum of the individual's observed genotypes weighted by the estimated coefficients. We calculated a residualized phenotype for each individual by subtracting the observed lipid level from the predicted lipid level based on the common SNPs. The observed lipid levels were either obtained off treatment or adjusted for lipid-lowering treatment by dividing the observed value by 0.7. Externally standardized residuals were created to assess the statistical significance of each individual's residualized phenotype. We used a threshold of ≤0.01 (a Bonferroni correction for the average number of individuals sequenced in each family) to define a significant residualized score.
Results
We performed exome sequencing on 213 selected individuals from the 41 families with suspected monogenic inheritance of extreme lipid levels, with a median of 4 individuals selected per kindred. On average, the mean coverage of targeted bases for each individual was 103. We identified an average of 12 544 nonsynonymous single nucleotide variants and 802 insertion/deletions per individual. Within each kindred, we used standard approaches to identify candidate variants 15 ( Figure II in the Data Supplement). In 5 families (12%), we identified likely pathogenic variants (Table) in genes previously proven to cause monogenic dyslipidemias (known lipid genes, Table I in the Data Supplement). We also identified the genetic basis in 3 families after follow-up analysis of their candidate variants ( Figure I in the Data Supplement, Families A1 23 , A10 30 , and A13 24 ) and one after considering the effect of common genetic variants (described below), bringing the total to 9 (22%; 95% confidence interval [9.3%, 34.7%]; see Table;  Table II in the Data Supplement for details).
In the remaining 32 families, however, the number of candidate variants ranged from 0 to 287, without obvious genetic etiologies, despite follow-up analyses. We sought to understand potential reasons for the lack of novel gene discovery and identified 3 main confounders: (1) an inability to identify potentially causal variants caused by imperfect sequencing coverage; (2) an inability to identify the causal variant among hundreds of shared variants within families; and (3) an inability to identify the effect of complex genetics using exome sequencing.
To successfully discover a causal variant, the variant must first be identified. We find that despite high average coverage across the exome (on average 89% of targeted bases are covered with ≥20 reads; see Figure 1A ), a small but substantial portion of the exome is poorly covered across all affected individuals. Across the known lipid genes, we find affected individuals have, on average, 3.7% of targeted bases covered with ≤10 sequencing reads ( Figure 1A) , a sequencing depth that provides 99% confidence of observing a rare allele at least twice. At these positions, there is a chance we would fail to identify a variant in the affected individual with shallow sequencing coverage, and these positions would then be removed from consideration under the assumption of complete penetrance without phenocopies.
Family A1 ( Figure I in the Data Supplement) illustrates this problem. In this family, affected individuals were identified to harbor a pathogenic APOE deletion. 23 Initially, the pathogenic deletion (p.Leu167del) was only identified in 2 of 3 affected individuals using exome sequencing and was thus removed from further consideration. When orthogonal methods (linkage analysis and sequencing under linked peaks) identified p.Leu167del as a candidate, we performed Sanger sequencing to confirm the presence of the deletion in all affected individuals. This mutation occurs in the last exon of APOE which is difficult to capture and sequence with NGS 31 and has the lowest coverage and highest GC content of the known lipid genes (Tables III and IV in the Data Supplement) . The individual in Family A1 initially misclassified by NGS only had one sequencing read at that position of the genome. Across the remainder of the exome, we find affected individuals have, on average, 6.4% of targeted bases covered with ≤10 sequencing reads ( Figure 1A ). This effect seems to be independent of overall sequencing depth ( Figure III in the Data Supplement), suggesting it cannot be solved simply by sequencing to deeper overall coverage. It has been previously suggested that exome sequencing fails to identify the genetic basis of some strongly inherited conditions because of causal noncoding mutations 32 ; another explanation could be that the causal variant is present in the coding region but hitherto unidentified.
Second, we find a confounding effect from the many rare alleles within families that also segregate with the phenotype by chance. This is highlighted by examining the total number of candidate variants even in families harboring pathogenic variants in a known lipid gene. In these families, between 2 and 346 additional variants remain candidates at the end of the analysis and would be considered potentially causal if a pathogenic variant had not been identified. This is similar to the number of variants remaining in families without known genetic causes (range 0-287; see Figure 1B ), highlighting the vast amount of rare variation private to families that segregates with the disease phenotype merely by chance.
Third, we also find that the effect of complex genetics in families with suspected monogenic dyslipidemias can be substantial. Both LDL-C and HDL-C levels are influenced by multiple common genetic loci 18 ; we 18 and others 33 have previously demonstrated that polygenic inheritance may be sufficient to explain extreme lipid phenotypes. To address this possibility in the families sequenced in the present study, we genotyped a set of common genetic variants robustly associated with lipid traits in genome-wide association studies. 18 Using these common variants, we created a polygenic score and calculated a residualized phenotypic z-score, effectively assigning a level of statistical significance to each individual's lipid level after correcting for that individual's burden of common lipid-related alleles ( Figure IV in the Data Supplement).
As a proof-of-principle, we find highly significant scores for individuals from families A9 and B2, in which pathogenic PCSK9 and APOB mutations, respectively, perfectly segregate with disease status, indicating that common genetic factors are not sufficient to explain the phenotype in these families (Table V in the Data Supplement). In contrast, of the families without a readily apparent genetic answer, we find 6 (15% of all families), where either all affected individuals have nonsignificant scores or only one affected individual retains a significant score, suggesting that the burden of common alleles is sufficient to largely explain the extreme phenotype in these families (Table VI and Figure V in the Data Supplement).
We also find this approach can help refine phenotypic definitions within families. In Family A7, an initial analysis using clinically defined affection status (Figure 2A ) yielded 17 candidate variants; additional analyses were unable to identify a causal variant from this list. Using the polygenic score, we found individuals III-1 and III-2 had LDL-C levels that were largely explained by a burden of common variants, whereas individuals II-3 and III-5 had highly significant residualized scores (Table VII in the Data Supplement). An analysis using these updated phenotypes identified a candidate variant in LDLR (p.E228K, also known as FH Modena, previously shown to be pathogenic 25 ) that was subsequently confirmed to ‡To our knowledge, this mutation has not been previously identified as causing autosomal dominant hypercholesterolemia (ADH). However, this mutation occurs at a highly conserved position within the highly conserved LDLR-binding domain of ApoB where other missense mutations causing ADH have been identified. A threonine for alanine substitution at this position is computationally predicted to be damaging. §This mutation has been previously identified as causing ADH in other families. 5 ║A report detailing this mutation has been previously published. 20 #To our knowledge, this mutation has not been previously identified as causing familial hypobetalipoproteinemia (FHBL); however, this is expected type of causal mutation for FHBL, inducing a premature truncation of ApoB. **To our knowledge, this mutation has not been previously identified as causing Tangier disease. However, this mutation is in the second conserved nucleotidebinding domain (ATP binding cassette) within the Walker A/P-loop of ABCA1. It affects the amino acid residue position corresponding to the equivalent Asparagine in the 1st nucleotide binding domain, which is known to be causal in Tangier disease. 21, 22 The sequences are GHNGAGKTTTM (domain 1) and GVNGAGKSSTF (domain 2) (the mutated residue is underlined).
‡ ‡A report of this mutation causing ADH has been previously published. 23 ‡ ‡A report detailing this mutation has been previously published. 24 § §This mutation, also known as FH-Jerusalem, has been previously identified as causing familial hypercholesterolemia. 25, 26 perfectly segregate with extreme LDL-C levels in the extended kindred ( Figure 2B ). We attempted to extend these findings to a non-European population and found similar results in families of Japanese descent with extreme LDL-C levels ( Figure VI in the Data Supplement). In this analysis, a pathogenic variant in LDLR was found in one family ( Table VIII in the Data Supplement) , whereas there was no clear molecular basis in the remaining 3, resulting in a 25% success rate. We found similar levels of imperfect sequence coverage and numbers of rare variants segregating within the family ( Table IX in 
Discussion
The present study summarizes our experience using exome sequencing to map novel genes in families with a suspected Mendelian dyslipdemia. After sequencing the exome in 213 individuals across 41 kindreds, we find this technique identifies a likely causal variant in 22% of cases. Three of these families harbor causal mutations in known lipid genes that were excluded by candidate sequencing before entry into this study, reconfirming previous results that candidate gene sequencing can fail to identify causal mutations in candidate genes that are subsequently identified via NGS. 34 Notably, we did not identify any novel monogenic dyslipidemia genes. From the remainder of the families in our study, we identify evidence of polygenic inheritance in 15%. We are, however, currently unable to define the genetic basis in the remaining 63% of families ( Figure 3) .
Several conclusions emerge from these results. First, from this empirical evaluation, we find the yield of exome sequencing as a tool for novel gene mapping to be modest. Multiple reports detailing the success of this technique have been published since 2009 2 ; however, these reports may be susceptible to the well-known bias to publish positive results. Overall, we are unaware of reports detailing the overall success rate of exome sequencing. Our study highlights the real-world challenges in using this technique for mapping novel genes in Mendelian disorders and seems to reflect the collective experience in monogenic dyslipidemias as evidenced by the current literature. We are unaware of a Mendelian dyslipidemia gene other than ANGPTL3 35 that has been identified using exome sequencing.
Second, we identified several technical issues that have not been previously highlighted that adversely affected our ability to discover novel genes. An underlying assumption when mapping genes with NGS is that all potentially causal variants will be identified. Our study reveals some of the limitations of exome sequencing which may be useful to address in future design of research or clinical sequencing studies.
Third, we find a substantial concerted effect of common lipid-related alleles that seems to result in extreme Figure 1 . Selected metrics from exome sequencing analysis. A, Percent targeted bases across the exome definition supported by ≤20 sequencing reads (Red) or ≤10 sequencing reads (Blue) or across genes previously identified to cause monogenic dyslipidemia supported by ≤10 sequencing reads (Green). B, Number of candidate variants after analysis for families with a suspected pathogenic variant in a gene known to cause monogenic dyslipidemia (orange) compared with families without known cause (brown). P refers to the P value from the Kolmogorov-Smirnov test in testing for differences between the distributions. phenotypes in some individuals and families. A similar effect has been shown previously for samples drawn from the extremes of the population distribution of plasma lipids 18 and in a significant proportion of mutation-negative probands who underwent clinical genetic testing for familial hypercholesterolemia. 33 Although only ≈10% of the total phenotypic variance in lipid traits is explained by the common variants genotyped in our study, 18 by removing this variance, we were able to create a more refined phenotype and enrich for genetic factors not present in the set of common variants. We show that incorporating this information may inform genetic mapping as we have demonstrated above in Family A7.
Our study has several limitations. Exome sequencing has limited reliability to identify large structural variants, and although we did consider small insertions and deletions, this technique is less reliable in identifying these compared with single nucleotide substitutions. Reliable incorporation of these forms of genetic variation might identify additional candidates. 36 We also did not consider genome-wide linkage data because of the small size of the pedigrees, and incorporating such information has the potential to reduce the number of candidates. 37 From a technical perspective, it is possible that other exome capture reagents or sequencing platforms (including longer reads) may result in more complete coverage. Finally, it is important to note this experience may not necessarily generalize to other phenotypes. For example, one might expect the yield to be higher for studying extreme syndromic phenotypes less susceptible to the influences of polygenic inheritance and environmental factors.
Addressing the 3 problematic areas outlined above has the potential to improve the success of gene mapping. Whole genome sequencing could be used to remove the bias of target definition and hybrid selection inherent in exome sequencing, although we recognize certain portions of the genome will remain recalcitrant to NGS technology. 38 The process for identifying causal rare alleles within families can be improved as larger population-based sequencing studies are performed and as better high-throughput functional assays are developed. Sequencing more distantly related relatives can decrease the total number of shared alleles; however, investigators typically resort to exome sequencing in small pedigrees for which linkage analysis has been intractable. Finally, as we identify additional alleles contributing to complex phenotypic traits, we can use these findings to inform family based genetic studies by both selecting families without significant polygenic inheritance and refining phenotypic definitions within families. 
